Q&A: Unpacking The Latest VALID Act For Diagnostics
Covington & Burling partner Scott Danzis tells Medtech Insight why diagnostics developers and labs should keep an eye on the third iteration of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act – reintroduced in the US Senate on 24 June – and why the bill has a better shot at becoming law this time.
You may also be interested in...
Abbott Preps For Potential VALID Act For Diagnostics While Pushing For More Clarity
Abbott says it’s preparing for the possible passage of legislation that would, among other things, create a new regulatory framework for diagnostic tests. But the manufacturer is also asking for more specificity around the bill’s quality requirements.
Q&A: FDA’s LDT Inaction Catches Veteran Attorney Off-Guard
Industry experts expected the US FDA to swiftly reverse a Trump-administration policy blocking oversight of lab-developed tests. Its inaction has one former agency attorney wondering why.
Once A Cheerleader For Latest VALID Act For Diagnostics, Pew Now Has Some Reservations
Public policy group The Pew Charitable Trusts is concerned that the latest iteration of the Verifying Accurate, Leading-edge IVCT Development (VALID) Act prioritizes a faster time to market over patient safety. The group had previously signed onto a letter praising the proposed legislation, which aims to build a new regulatory framework for diagnostics in the US.